SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Role of genetic assessments- Quentin Anstee, BSc, MB BS, PhD, MRCP(UK), FRCPView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017MRI; what can it deliver- Claude Sirlin, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Circulating nucleic acids and combination panels- Sven Francque, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Collaboration in action - Innovative Medicines Initiative- Quentin Anstee, BSc, MB BS, PhD, MRCP(UK), FRCPView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Collaboration in action - Foundation for the National Institutes of Health- Roberto Calle, MD, FACE, FACPView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Session 2: Pathways to biomarker qualification and acceptance- Chris Leptak, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017EU perspective- Elmer Schabel, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Innovation in histological assessment of NASH- Pierre Bedossa, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2017Opening lecture: A pathologist, a radiologist and a hepatologist walked into a bar- Brent Neuschwander-Tetri, MDView Slideset
VideoRespiDART 2018Discovery and development of novel and potent non-fusion inhibitors of RSV | Michael Rhodin, PhDView Video
VideoRespiDART 20183D Human epithelial models to study respiratory virus pathogenesis | Samuel Constant, PhDView Video
